Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Malignancies 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Rabeprazole × 1 year × Clear all
NCT07076914 2025-07-22

PPI-PROTECT

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Not yet recruiting
58 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡